Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization

Circulation Journal

Volumn 72, Issue 9, 2008, Pages 1499-1505

  Kato, Koji ^a   Sato, Naoki ^a   Yamamoto, Takeshi ^a   Iwasaki, Yu Ki ^a   Tanaka, Keiji ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Contrast induced nephropathy; Coronary angiography; Cystatin C; L FABP; Percutaneous coronary intervention

Indexed keywords

ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; IOHEXOL; IOMEPROL; N ACETYL BETA GLUCOSAMINIDASE; OMUNIPAQUE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTRAST MEDIUM INDUCED NEPHROPATHY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS;

ACETYLGLUCOSAMINE; ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLOBULINS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CONTRAST MEDIA; CYSTATIN C; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; HEART CATHETERIZATION; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 50449090439     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-07-1006     Document Type: Article

References (37)

1. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
3. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: A prospective controlled study. N Engl J Med 1989; 320: 143-149.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
5. Weinrauch LA, Healy RW, Leland OS Jr, Goldstein HH, Kassissieh SD, Libertino JA, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med 1977; 86: 56-59.
6. Zhang Q, Ma CS, Nie SP, Du X, Lv Q, Kang JP, et al. Prevalence and impact of renal insufficiency on clinical outcomes of patients undergoing coronary revascularization. Circ J 2007; 71: 1299-1304.
7. Pitsavos C, Kourlaba G, Panagiotakos DB, Kogias Y, Mantas Y, Chrysohoou C, et al. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: The GREECS study. Circ J 2007; 71: 9-14.
8. Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, et al. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. Circ J 2006; 70: 954-959.
9. Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: A prospective trial. Ann Intern Med 1989; 110: 119-124.
10. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
11. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83.
12. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165: 1243-1255.
13. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
15. Nakamura T, Sugaya T, Ebihara I, Koide H. Urinary liver-type fatty acid-binding protein: Discrimination between IgA nephropathy and thin basement membrane nephropathy. Am J Nephrol 2005; 25: 447-450.
16. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci 2005; 330: 161-165.
17. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28: 2728- 2732.
18. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [Modification of Diet in Renal Disease Study Group]. Ann Intern Med 1999; 130: 461-470.
20. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. Can Med Asooc J 2005; 172: 1461-1471.
21. Lautin EM, Freeman NJ, Schoenfeld AH, Bakal CW, Haramati N, Friedman AC, et al. Radiocontrast-associated renal dysfunction: Incidence and risk factors. Am J Roentgenol 1991; 157: 49-58.
22. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
23. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C: A new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101: 875-881.
24. Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102: 173-178.
25. Orlando R, Mussap M, Plebani M, Piccoli P, De Martin S, Floreani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48: 850-858.
26. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: Use in cancer patients before and during chemotherapy. Clin Chem 2000; 46: 193-197.
27. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998; 49: 221-225.
28. Tepel M, Zidek W. N-Acetylcysteine in nephrology; contrast nephropathy and beyond. Curr Opin Nephrol Hypertens 2004; 13: 649-654.
29. Brezis M, Rosen S. Hypoxia of the renal medulla: Its implications for disease. N Engl J Med 1995; 332: 647-655.
30. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: A consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999; 9: 1602-1613.
31. Morcos SK, Epstein FH, Haylor J, Dobrota M. Aspects of contrast media nephrotoxicity. Eur J Radiol 1996; 23: 178-184.
32. Morcos SK, El Nahas AM. Advances in the understanding of the nephrotoxicity of radiocontrast media. Nephron 1998; 78: 249-252.
33. Morcos SK, Brown PW, Oldroyd S, el Nahas AM, Haylor J. Relationship between the diuretic effect of radiocontrast media and their ability to increase renal vascular resistance. Br J Radiol 1995; 68: 850-853.
34. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med 2005; 145: 125-133.
35. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006; 374: 1-7.
36. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98: 14K-20K.
37. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27K-36K.